Search

Sustainability

Actions we're taking to reduce the environmental impact of our flagship event: the EHA Congress.

Read more

Board elections

Shape the future of EHA by taking part in our 2025 Board election. Nominations closed on February 9, 2025. The ballot will open on April 8, 2025.

Read more

Adding elotuzumab to standard treatment for multiple myeloma significantly reduced the risk of disease progression, with benefits sustained at two years

ELOQUENT-2, which evaluated elotuzumab in combination with lenalidomide and dexamethasone, is the first Phase III study to demonstrate the benefit of directly activating the immune system in the treatment of patients with relapsed or refractory multiple myeloma.

Read more

EHA attends the EuNet-INNOCHRON Final Conference

The EuNet-INNOCHRON Final Conference, a significant event in the field of hematology, took place in Chania, Crete, Greece from April 4-6, 2024.

Read more

EHA Lymphoma Group

The EHA Lymphoma Group (EHA LyG) is a specialized working group that was established in 2014.

Read more